The 58 AML cases at presentation were sequentially collected: 6 TP53 mutated; 4 CBFB::MYH11; 4 RUNX1::RUNX1T1; 13 myelodysplasia (MDS) related (rel), encompassing molecular and genetic subtypes; 13 PML::RARA (APL); 9 NPM1 mutated; 2 KMT2A rearranged (KMT2Ar); and 7 AML, not otherwise specified (NOS). This evidence concerns the gene RUNX1 and acute myeloid leukemia.